Subtype
Bile Duct Neoplasm
CI-CAN-00000563Explore in graph →
Non-malignant224 active trials3 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000563Explore in graph →
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT04099888 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer(RELEASE) | terminated | Phase 2 | 41 | PCI Biotech ASINDUSTRY | 14 | Sep 11, 2023 |
| NCT03003065 | Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers(PDT) | completed | Phase 2 | 10 | Chinese University of Hong KongOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04566133 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04072445 | Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | terminated | Phase 2 | 143 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Jul 3, 2023 | clinicaltrials |
| NCT03278106 | TAS-102 in Treating Advanced Biliary Tract Cancers | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05911425 | Combined Treatment of Treated Bile Duct Cancer(CHOL) | unknown | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02520141 | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03473574 | Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients(IMMUCHEC) | completed | Phase 2 | 128 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03820310 | Clinical Trial of Autologous Tcm Immunotherapy in ICC | unknown | Phase 2 | 20 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT01845337 | Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine(TOFFEE) | completed | Phase 2 | 59 | University of EdinburghOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Binkui LiOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03895970 | Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors | completed | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02821754 | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT05672537 | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | unknown | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT00286013 | Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma | completed | Phase 2 | 24 | University Hospital, GhentOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03079427 | Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma | completed | Phase 2 | 101 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04076761 | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma(MOCHA) | terminated | Phase 2 | 8 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | terminated | Phase 2 | 17 | Delcath Systems Inc.INDUSTRY | 1 | Oct 17, 2022 | clinicaltrials |
| NCT03769753 | Trial of IRE in Cholangiocarcinoma | completed | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05535647 | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Walid Shaib, MDOTHER | 0 | Jun 29, 2022 | clinicaltrials |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 0 | Jun 15, 2022 | clinicaltrials |
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | terminated | Phase 2 | 3 | AIO-Studien-gGmbHOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC | withdrawn | Phase 2 | 0 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT02591030 | Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours(AMEBICA) | completed | Phase 2 / Phase 3 | 191 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04648319 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | terminated | Phase 2 | 1 | American University of Beirut Medical CenterOTHER | 3 | Feb 23, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | terminated | Phase 2 | 4 | Aiwu Ruth He, MDOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT02392637 | Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT05207735 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.(SCRCA) | unknown | Phase 2 | 73 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05148143 | RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor(RALOXBTC) | unknown | Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT03111732 | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03486678 | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC | completed | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT02128282 | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | completed | Phase 1 / Phase 2 | 127 | Senhwa Biosciences, Inc.INDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Sep 15, 2023source: clinicaltrials